Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: First results of a phase I/II study

BMC Cancer

Volumn 7, Issue , 2007, Pages

  Gagel, Bernd ^a   Piroth, Marc ^a   Pinkawa, Michael ^a   Reinartz, Patrick ^a   Krohn, Thomas ^a   Kaiser, Hans J ^a   Stanzel, Sven ^a   Breuer, Christian ^a   Asadpour, Branka ^a   Schmachtenberg, Axel ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; DIURETIC AGENT; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NAVELBINE; OXYGEN; PACLITAXEL; STEROID; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; VINBLASTINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD PRESSURE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGITIS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; KIDNEY METASTASIS; LEUKOPENIA; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; ODYNOPHAGIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; ADJUVANT THERAPY; CANCER STAGING; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROBABILITY; PROGNOSIS; REMISSION; RISK ASSESSMENT; SCINTISCANNING; SURVIVAL; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CONFIDENCE INTERVALS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROBABILITY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN; VINBLASTINE;

EID: 34547416716     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-7-112     Document Type: Article

References (28)

1. Albain KS Crowley JJ Turrisi AT III Gandara DR Farrar WB Clark JI Beasley KR Livingston RB Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group phase II study, SWOG 9019 J Clin Oncol 2002 20 3454-3460 10.1200/JCO.2002.03.055 12177106
2. Armstrong JG Target volume definition for three-dimensional conformal radiation therapy of lung cancer Br J Radiol 1998 71 587-594 9849380
3. Chen YM Perng RP Yang KY Liu TW Tsai CM Ming-Liu J Whang-Peng J A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer Chest 2000 117 1583-1589 10.1378/chest.117.6.1583 10858387
4. Choy H Akerley W Safran H Graziano S Chung C Williams T Cole B Kennedy T Multi-institutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer J Clin Oncol 1998 16 3316-3322 9779707
5. Clopper CJ Pearson ES The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 1934 26 404 ff 10.1093/biomet/26.4.404
6. De Ruysscher D Wanders S Minken A Lumens A Schiffelers J Stultiens C Halders S Boersma L Baardwijk A Verschueren T Hochstenbag M Snoep G Wouters B Nijsten S Bentzen SM Kroonenburgh M Ollers M Lambin P Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: A planning study Radiother Oncol 2005 77 5-10 10.1016/j.radonc.2005.06.014 16019093
7. Dillman RO Herndon J Seagren SL Eaton WL Jr Green MR Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial J Natl Cancer Inst 1996 88 1210-1215 10.1093/jnci/88.17.1210 8780630
8. Fournel P Robinet G Thomas P Souquet PJ Lena H Vergnenegre A Delhoume JY Le Treut J Silvani JA Dansin E Bozonnat MC Daures JP Mornex F Perol M Randomized phase III trail of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer: Group Lyon-Saint Etienne d'Onncologie Thoracique - Group Francaise de Pneumo-Cancerologie NPC 95-01 Study J Clin Oncol 2005 23 5910-5917 10.1200/JCO.2005.03.070 16087956
9. Gagel B Piroth M Michael Pinkawa M Patrick Reinartz P Zimny M Fischedik K Stanzel S Breuer C Skobel E Asadpour B Schmachtenberg A Buell U Eble MJ Gemcitabine Concurrent with Thoracic Radiotherapy after Induction Chemotherapy with Gemcitabine/Vinorelbine in Locally Advanced Non-Small Cell Lung Cancer Strahlenther Onkol 2006 182 263-269 10.1007/ s00066-006-1485-0 16673059
10. Gagel B Reinartz P Demirel C Kaiser HJ Zimny M Piroth M Pinkawa M Stanzel S Asadpour B Hamacher K Coenen HH Buell U Eble MJ [18F]fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: A feasibility study BMC Cancer 2006 6 51 1456976 16515707 10.1186/1471-2407-6-51
11. Giaccone G New drugs for the management of lung cancer Br J Hosp Med 1996 55 634-638 8762124
12. Gould MK Kuschner WG Rydzak CE Maclean CC Demas AN Shigemitsu H Chan JK Owens DK Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: A meta-analysis Ann Intern Med 2003 139 879-892 14644890
13. Kalff V Hicks RJ MacManus P Binns DS McKenzie AF Ware RE Hogg A Ball DL Clinical impact of [18F]fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: A prospective study J Clin Oncol 2001 19 111-118 11134203
14. Krajnik G Mohn-Staudner A Thaler J Greil R Schmeikal S Marhold F Deutsch J Preiss P Malayeri R Schafer-Prokop C Wein W Huber H Pirker R Vinorelbine-gemcitabine in advanced non-small cell lung cancer (NSCLC): an AASLC phase II trial Ann Oncol 2000 11 993-998 10.1023/ A:1008370704612 11038036
15. Laack E Mende T Benk J Chemaissani A Scholtze J Lorenz C Niestroy A Dalhoff K Muller T Walter T Durk H Edler L Hossfeld DK Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer, a phase II trial Eur J Cancer 2001 37 583-590 10.1016/ S0959-8049(00)00441-X 11290433
16. Le Chevalier T Arriagada R Quoix E Ruffie P Martin M Tarayre M Lacombe-Terrier MJ Douillard JY Laplanche A Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients J Natl Cancer Inst 1991 83 417-423 10.1093/jnci/83.6.417 1847977
17. Lorusso V Carpagnano F Frasci G Panza N Di Rienzo G Cisternino ML Napoli G Orlando S Cinieri S Brunetti C Palazzo S De Lena M Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer J Clin Oncol 2000 18 405-411 10637256
18. Mountain CF Revisions in the international system for staging lung cancer Chest 1997 111 1710-1717 9187198
19. Rancati T Ceresoli GL Gagliardi G Schipani S Cattaneo GM Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study Radiother Oncol 2003 67 275-283 10.1016/ S0167-8140(03)00119-1 12865175
20. Sause WT Scott C Taylor S Johnson D Livingston R Komaki R Emami B Curran WJ Byhardt RW Turrisi AT Dar AR Cox JD Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer J Natl Cancer Inst 1995 87 198-205 10.1093/jnci/87.3.198 7707407
21. Schaake-Koning C van den Bogaert W Festen DO Hoogenhout J van Houtte P Kirkpatrick A Koolen M Maat B Nijs A Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer N Engl J Med 1992 326 524-530 1310160
22. Schmücking M Baum RP Bonnet R Junker K Müller K-M Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment Pathologe 2005 26 3 178-190 10.1007/ s00292-005-0758-1 15800765
23. Shewach DS Hahn TM Chang E Hertel LW Lawrence TS Metabolism of 2′,2′difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells Cancer Res 1994 54 3218-3223 8205542
24. Shewach DS Lawrence TS Radiosensitization of human solid tumor cell lines with gemcitabine Semin Oncol 1996 23 Suppl 10 65-71
25. Trodella L Granone P Valente S Turriziani A Macis G Corbo GM Margaritora S Cesario A D'Angelillo RM Gualano G Ramella S Galetta D Cellini N Phase I Trial of Weekly Gemcitabine and Concurrent Radiotherapy in Patients with Inoperable Non-Small-Cell Lung Cancer J Clin Oncol 2002 20 804-810 10.1200/JCO.20.3.804 11821464
26. Van Putten J Price A van der Leest A Gregor A Little FA Groen HJM A Phase I Study of Gemcitabine with Concurrent Radiotherapy in Stage III, Locally Advanced Non-Small Cell Lung Cancer Clinical Cancer Research 2003 9 2472-2477 12855620
27. Vansteenkiste JF Stroobants SG Dupont PJ De Leyn PR De Wever WF Verbeken EK Nuyts JL Maes FP Bogaert JG FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group Eur J Nucl Med 1998 25 1495-501 10.1007/s002590050327 9799345
28. Zatloukal P Petruzelka L Zemanova M Havel L Janku F Judas L Krepela E Fiala P Pecen L Concurrent versus sequential radiochemotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer Lung Cancer 2004 46 87-98 10.1016/j.lungcan.2004.03.004 15364136